Technology News and Research

RSS

JAOtech to unveil world's first large screen ultra-thin medical LED TV

JAOtech, the leading manufacturer of bedside Smart Terminals for hospitals, is to unveil the world's first large screen ultra-thin medical LED TV with built-in computer, aimed specifically at healthcare applications such as patient entertainment and clinical access.

29 Jan 2011

New research shows CEUS can improve diagnosis of variety of medical conditions in children

New research released here Thursday shows that "contrast-enhanced ultrasound" can safely improve the diagnosis of a variety of medical conditions in children - without exposing them to ionizing radiation.

29 Jan 2011

XDx establishes $12.5 million multi-draw term loan facility with GE Capital

XDx, a San Francisco-based molecular diagnostics company focused on non-invasive gene expression-based tests for the monitoring of organ transplant rejection and autoimmune diseases, announced today that it has established a $12.5 million senior secured multi-draw term loan facility with GE Capital, Healthcare Financial Services.

28 Jan 2011

NCQA to release new standards for Patient-Centered Medical Home program

On January 31, the National Committee for Quality Assurance will release new standards for its Patient-Centered Medical Home program. The new standards call on medical practices to be more patient-centered, and reinforce federal "meaningful use" incentives for primary care practices to adopt health information technology.

28 Jan 2011

WOUNDS article profiles efficacy of Quick-Med's antimicrobial BIOGUARD dressings

Quick-Med Technologies, Inc. announced today that the February 2011 issue of WOUNDS, the leading peer-reviewed journal in the wound care field, will feature an article authored by Quick-Med's Albina Mikhaylova, PhD. The article profiles the safety and antimicrobial efficacy of cutting edge antimicrobial dressings employing Quick-Med's patented NIMBUS technology and marketed by Derma Sciences, Inc. under its BIOGUARD® trademark.

28 Jan 2011

NIH awards CCTSI $2.2 million grant to advance personalized medicine

A federal grant totaling $2.2 million shows how the University of Colorado School of Medicine and Anschutz Medical Campus are using technology to advance the cutting-edge field of personalized medicine -- tailoring treatments to the individual based on their genetic make-up.

28 Jan 2011

Call for swift bipartisan agreement to make scientific research a high priority

The members of the Task Force on American Innovation - a coalition of industry, universities, and professional societies - agree with the President's comments tonight that the country needs both strong measures to reduce federal budget deficits and increased investment in scientific research, particularly in the physical sciences and engineering. We believe strongly that both deficit reduction and these targeted investments are key to our nation's long-term economic growth and national security.

28 Jan 2011

EHSI examines business plans and product lines of OceanBASIS

Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.

28 Jan 2011

APS calls for bipartisan support for greater investment in scientific research

The American Physical Society (APS), the nation's largest organization of physicists, takes special note of President Obama's speech last night that increasing scientific research and innovation and improving education are crucial to our nation's long-term economic growth.

28 Jan 2011

Effective fusion of consumer technology and front line medicine needed

Government spending cuts and the high cost of distributed healthcare provision could mean a major shift toward home-based patient care. Lack of resource, increased travel time and an aging population is leading some to consider a more viable alternative. However, limited broadband Internet access in remote areas means that joined up policy changes are needed to ensure an effective solution is achieved.

28 Jan 2011

Bioniche Life Sciences joins Australian Securities Exchange

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has joined the official list of the Australian Securities Exchange (ASX) and its securities are now trading on that exchange under the code "BNC".

28 Jan 2011

Soligenix and CU enter definitive license agreement for novel vaccine thermostabilization technology

Soligenix, Inc., a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures.

28 Jan 2011

Magnetic nanoparticles for ovarian cancer treatment

A paper published in the January issue of the journal Nanomedicine could provide the foundation for a new ovarian cancer treatment option - one that would use an outside-the-body filtration device to remove a large portion of the free-floating cancer cells that often create secondary tumors.

28 Jan 2011

Discovery of aldose reductase enzyme can result in new therapies for asthma and COPD

Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease.

28 Jan 2011

Boston Scientific reports first U.S. use of Blazer Open-Irrigated Catheter in BLOCk-CTI clinical trial

Boston Scientific Corporation today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI clinical trial. BLOCk-CTI is a prospective, randomized trial evaluating the safety and effectiveness of the Blazer Open-Irrigated Catheter in patients with sustained or recurrent Type 1 atrial flutter.

28 Jan 2011

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

The University of Massachusetts Medical School and Lundbeck today announced a research collaboration aimed at further development of a targeted therapy to slow or halt the progression of Huntington's disease.

28 Jan 2011

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi's sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.

28 Jan 2011